Funder
Japan Society for the Promotion of Science
Astellas Pharma
Subject
Histology,Physiology,Endocrinology, Diabetes and Metabolism
Reference37 articles.
1. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives;Takeuchi;Chem Pharm Bull,1998
2. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy;Russell;Ann. N. Y. Acad. Sci.,2007
3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras;Luckman;J. Bone Miner. Res.,1998
4. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro;Fisher;Proc. Natl. Acad. Sci. U. S. A.,1999
5. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates;van Beek;Biochem. Biophys. Res. Commun.,1999